Trial Profile

An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira in Patients With Rheumatoid Arthritis on Concomitant Methotrexate

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Registrational
Acronyms ARABESC-OLE
Sponsors Fujifilm Kyowa Kirin Biologics

Most Recent Events

15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
15 Feb 2018 Status changed from active, no longer recruiting to completed.
08 Nov 2017 Results from parent and extension studies (ARABESC and ARABESC-OLE) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com